Biowatch

When Other Biologics Fail: Skyrizi Drives Steroid-Free Remission in Over Half of Hard-to-Treat Crohn’s Patients

When Other Biologics Fail: Skyrizi Drives Steroid-Free Remission in Over Half of Hard-to-Treat Crohn’s Patients

Crohn’s disease remains one of the most challenging inflammatory bowel diseases to manage. Patients with refractory—or treatment-resistant—Crohn’s...
From AI Medicine to K-Beauty: Medi Expo Korea 2026 Set for Record-Breaking 350-Company Showcase

From AI Medicine to K-Beauty: Medi Expo Korea 2026 Set for Record-Breaking 350-Company Showcase

MEDI EXPO KOREA 2026, a premier summer showcase of South Korea’s healthcare industry and shifting global medical trends, is set to open its doors...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
AI Fills the Care Gap: VUNO’s DeepCARS Cuts In-Hospital Cardiac Arrests by 21% Without Rapid Response Teams

AI Fills the Care Gap: VUNO’s DeepCARS Cuts In-Hospital Cardiac Arrests by 21% Without Rapid Response Teams

Unlike intensive care units , general hospital wards do not feature continuous, around-the-clock patient monitoring.
SCL Healthcare Secures U.S. Patent for Genetic Test Predicting Metabolic Syndrome Risk

SCL Healthcare Secures U.S. Patent for Genetic Test Predicting Metabolic Syndrome Risk

SCL Healthcare has successfully secured a U.S. patent for a novel genetic testing technology designed to predict an...
MSD Bets $510M on High-Quality Data to Fuel Post-Keytruda AI Drug Discovery

MSD Bets $510M on High-Quality Data to Fuel Post-Keytruda AI Drug Discovery

MSD, which has long dominated the global cancer market with its blockbuster immuno-oncology therapy Keytruda, is...
GC Wellbeing’s Laennec Injection Clears Phase 3 Hurdle for IV Drip Use, Boosting Growth Prospects

GC Wellbeing’s Laennec Injection Clears Phase 3 Hurdle for IV Drip Use, Boosting Growth Prospects

GC Wellbeing announced on June 16 that it has secured topline results demonstrating that its chronic liver disease...
Seers Surpasses 200 Adopting Hospitals for ‘thynC,’ Upgrading Operations for Rapid Scaling

Seers Surpasses 200 Adopting Hospitals for ‘thynC,’ Upgrading Operations for Rapid Scaling

Seers, a leading wearable artificial intelligence diagnostic monitoring company, is sharpening its commercial strategy...
Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell, a South Korean clinical-stage biotech company specializing in chimeric antigen receptor T-cell (CAR-T)...
RNA Therapy Emerges as Critical Fast-Track for Cholesterol Control After Heart Attacks

RNA Therapy Emerges as Critical Fast-Track for Cholesterol Control After Heart Attacks

Myocardial infarction and unstable angina are life-threatening medical emergencies that occur when the blood vessels...